Reuters
Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.
U.S.-listed shares of the Danish drugmaker were up 5.3%, while shares of GoodRx rose 34.2%.
Novo and rival Eli Lilly have expanded into direct-to-consumer sales for the highly effective and sought-after medicines, in part due to competition from online telehealth companies and pharmacies that sell cheaper compounded versions.
Novo already sells Wegovy, the weight-loss version of Ozempic, through its NovoCare pharmacy for $499. The latest offer is aimed at patients who do not have insurance coverage. More
It’s a trap!
OT but relevant? Have you noticed that Newsmax has made it into the BIG TIME. They now share all the pharmaceutical adds with all the major networks. Funny huh?
Obviously pharmaceutical companies could easily sell their products for far less than they do and still make obscene profits. Only when forced through competition (conveniently controlled by government to protect their profits) do they even consider offering reasonable prices. And of course the productive working middle class absorbs the costs so those “in need” can obtain their drugs at no cost. There’s a reason pharmaceutical companies have the largest lobby and spend the most on “political donations”.
InGod We TrustAll Others Pay Cash.“nasty-nodick” – mighty yt of you
If your insurance company reimburses you it might be a good deal for you and them.